On Nov 02, major Wall Street analysts update their ratings for $Regeneron Pharmaceuticals (REGN.US)$, with price targets ranging from $800 to $1,195.
Morgan Stanley analyst Terence Flynn maintains with a buy rating, and maintains the target price at $1,184.
BofA Securities analyst Alec Stranahan maintains with a sell rating, and adjusts the target price from $805 to $800.
Barclays analyst Carter Gould maintains with a buy rating, and adjusts the target price from $1,080 to $1,065.
UBS analyst Colin Bristow maintains with a buy rating, and adjusts the target price from $1,251 to $1,130.
Evercore analyst Cory Kasimov maintains with a buy rating, and maintains the target price at $1,170.
Furthermore, according to the comprehensive report, the opinions of $Regeneron Pharmaceuticals (REGN.US)$'s main analysts recently are as follows:
Regeneron's Q3 financial results surpassed expectations marginally in terms of revenue and more significantly in earnings per share. Nevertheless, this was eclipsed by the performance of the Eylea franchise. Concerns have been raised about the future of the Eylea franchise due to the impending introduction of a biosimilar version by a competitor. These concerns encompass not only the anticipated faster erosion of the standard dose's market share, which may be underestimated by the market, but also potential negative effects on the higher dose variant.
Recent pressures on Regeneron shares are seen as excessive, according to analysts. This sentiment follows reactions to developments with Pavblu and a less than favorable Q4 outlook for Eylea HD, coupled with unclear projections regarding Eylea's future growth.
The decline in Regeneron's stock value following Q3 earnings was somewhat unexpected, as it was presumed that the near- and long-term consensus estimates for the optho franchise were overly optimistic. Nevertheless, it is believed that Regeneron's intrinsic fair value is substantially higher than the current share price.
Regeneron's recent quarterly financials aligned with optimistic revenue projections and surpassed expectations on earnings growth. However, the company's stock continues to encounter challenges stemming from its Eylea franchise and the looming threat of biosimilar competitors. The anticipated impact of a biosimilar by a competing company is still uncertain, but the initial response suggests it may not be as significant as feared, particularly given the tepid reception of other similar biosimilars in the market. The market's reaction to the pace at which patients are transitioning to Eylea HD has further pressured the stock's performance.
Here are the latest investment ratings and price targets for $Regeneron Pharmaceuticals (REGN.US)$ from 9 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月2日，多家华尔街大行更新了$再生元制药公司 (REGN.US)$的评级，目标价介于800美元至1,195美元。
摩根士丹利分析师Terence Flynn维持买入评级，维持目标价1,184美元。
美银证券分析师Alec Stranahan维持卖出评级，并将目标价从805美元下调至800美元。
巴克莱银行分析师Carter Gould维持买入评级，并将目标价从1,080美元下调至1,065美元。
瑞士银行分析师Colin Bristow维持买入评级，并将目标价从1,251美元下调至1,130美元。
Evercore分析师Cory Kasimov维持买入评级，维持目标价1,170美元。
此外，综合报道，$再生元制药公司 (REGN.US)$近期主要分析师观点如下：
Regeneron的第三季度财务业绩在营业收入方面略微超出预期，在每股收益方面更是显著。然而，这一成绩被Eylea特许经营权的表现所掩盖。人们对Eylea特许经营权的未来提出了担忧，因为一家竞争对手即将推出生物类似药的版本。这些担忧不仅涵盖了预期的标准剂量市场份额可能更快侵蚀，而市场可能低估了这一点，而且还可能会对高剂量变体产生负面影响。
分析师认为，最近对Regeneron股票的压力被认为是过分的。这种看法源于对Pavblu的发展和Eylea HD第四季度前景不佳的反应，以及对Eylea未来增长前景的不明确预测。
Regeneron股价在第三季度财报后的下降在某种程度上是出乎意料的，因为人们认为视网膜业务特许经营权的近期和长期共识估计过于乐观。然而，人们认为Regeneron的固有公允价值远高于当前股价。
Regeneron最近的季度财务业绩符合乐观的营业收入预测，并在盈利增长方面超出预期。然而，由于其Eylea特许经营权以及生物类似竞争对手的潜在威胁，该公司的股票继续面临挑战。预计竞争公司推出的生物类似药的影响仍然不确定，但最初的反应表明，这种影响可能不像人们担心的那样显著，特别是考虑到市场上其他类似生物类似药的乏味接受情况。市场对患者转向Eylea HD的速度反应进一步给股价施加了压力。
以下为今日9位分析师对$再生元制药公司 (REGN.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
